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Abstract 30 
Streptococcus pneumoniae (Spn) is a common cause of respiratory infection, but also frequently 31 
colonizes the nasopharynx in the absence of disease. We used mass cytometry to study immune 32 
cells from nasal biopsy samples collected following experimental human pneumococcal challenge 33 
in order to identify immunological mechanisms of control of Spn colonization. Using 37 markers, we 34 
characterized 293 nasal immune cell clusters, of which 7 were associated with Spn colonization. B 35 
cell and CD8+CD161+ T cell clusters were significantly lower in colonized than in non-colonized 36 
subjects. By following a second cohort before and after pneumococcal challenge we observed that 37 
B cells were depleted from the nasal mucosa upon Spn colonization. This associated with an 38 
expansion of Spn polysaccharide-specific and total plasmablasts in blood. Moreover, increased 39 
responses of blood mucosal associated invariant T (MAIT) cells against in vitro stimulation with 40 
pneumococcus prior to challenge associated with protection against establishment of Spn 41 
colonization and with increased mucosal MAIT cell populations. These results implicate MAIT cells 42 
in the protection against pneumococcal colonization and demonstrate that colonization affects 43 
mucosal and circulating B cell populations.  44 
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Introduction 46 
Streptococcus pneumoniae (Spn) is a major cause of morbidity and mortality worldwide (1, 2). It is 47 
the most common bacterial cause of otitis media, pneumonia and meningitis in children (1). Risk 48 
factors for pneumococcal disease include very young or advanced age, co-infection with influenza, 49 
HIV infection, chronic lung disease, asplenia and smoking (3). 50 
However, nasopharyngeal colonization, or carriage, of Spn in the absence of disease is common, 51 
with approximately 50% of infants and 10% of adults colonized at any time (4). Carriage is an 52 
immunising event in both children and adults but is also important as a prerequisite of disease and 53 
as the source of transmission (5-8). Successful colonization by Spn depends on many factors 54 
including bacterial factors, niche competition with other microbes, evasion of mucociliary clearance 55 
and host nutrient availability as well as immunological control of Spn (9). Epidemiological and 56 
modelling data have demonstrated that the immunizing effect of carriage is likely mediated by a 57 
combination of serotype-dependent and serotype-independent mechanisms (10-12).  58 
The introduction of pneumococcal conjugate vaccines (PCV) has led to significant reductions in 59 
carriage prevalence of covered serotypes, leading to herd protection and a decrease in 60 
pneumococcal disease in unvaccinated adults in addition to conferring direct protection (13). 61 
However, only 13 of approximately 100 Spn serotypes are currently covered by PCVs and the 62 
elucidation of immune mechanisms that associate with the control of Spn carriage remains an area 63 
of active investigation (14). 64 
Mouse models have suggested that Th17-mediated recruitment of neutrophils and monocytes to the 65 
nasopharynx is the mechanism of control and clearance of Spn carriage (15-17). In contrast, 66 
depletion of B cells or CD8+ T cells did not impair the clearance of Spn in murine models (18, 19).  67 
Amplification of monocyte recruitment in an auto-feedback loop via CCL2 was found to be important 68 
for clearance, further supporting the role for these cells in control of carriage (20). Innate factors 69 
have also been implicated in murine models as disruption of IFN-α or interleukin-1 signalling is 70 
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associated with increased colonization (21, 22). Recently, we demonstrated using an experimental 71 
human pneumococcal challenge (EHPC) model that carriage leads to degranulation of nasal-72 
resident neutrophils and recruitment of monocytes to the nasal mucosal surface (23). These 73 
responses were impaired by co-infection with live attenuated influenza virus, which associated with 74 
increased carriage density (24). Protection against experimental carriage acquisition in an 75 
unvaccinated setting is further associated with the levels of circulating memory B cells, but not levels 76 
of IgG, directed against the Spn polysaccharide capsule (25). Following PCV, very high levels of IgG 77 
associate with protection against experimental carriage acquisition, likely by mediating Spn 78 
agglutination followed by mucociliary clearance (26, 27). However, the relative role of these and 79 
other adaptive and innate immune cell subsets in controlling Spn at the human nasal mucosa 80 
remains largely unknown (28). The relatively small number of cells that can be collected from the 81 
nasal mucosa using minimally-invasive nasal curettage has limited the capacity to analyse the role 82 
of cellular subsets in controlling Spn carriage at the human nasal mucosa (29).  83 
Here, we collected nasal biopsies under local anaesthesia following experimental human 84 
pneumococcal challenge. This allowed for a comprehensive analysis of mucosal immunity during 85 
Spn carriage as these samples yield substantially more cells than minimally-invasive curettes. Nasal 86 
mucosal samples were analysed using mass cytometry (CyTOF), a technique in which antibodies 87 
are labelled with rare earth metals and that enabled the investigation of 37 protein markers 88 
simultaneously on a single-cell level (30). This method is ideally suited to investigate the relative 89 
understudied mucosal immune populations as the large number of markers allow the identification 90 
of previously unknown cell subsets and markers. Indeed, CyTOF has recently provided new insights 91 
into alveolar macrophage subpopulations in the lung and innate lymphoid cells differentiation 92 
pathways in the gut (31, 32). By combining nasal biopsies and CyTOF, we were thus able to study 93 
in-depth the immunological role of innate and adaptive cell subsets at the human nasal mucosa and 94 
their role during pneumococcal colonization. 95 
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Results 97 
Characterization of nasal immune populations 98 
Twenty healthy subjects negative for natural pneumococcal carriage at baseline screening were 99 
challenged intranasally with type 6B Spn (Figure 1A and Table 1). Carriage state was assessed at 100 
days two and seven post challenge and a nasal biopsy was collected at ten days post challenge 101 
(Supplementary Video 1), the timepoint at which Spn starts to be cleared from the nose (33, 34). 102 
Eight subjects became colonized with Spn (carriage+), while twelve subjects remained carriage– 103 
(Figure 1A). Biopsies yielded a median of 2.3x105 cells (IQR: 1.6x105 - 3.2x105) per subject, 104 
approximately 90% of which were stromal cells, which were stained with a panel of thirty-eight 105 
antibodies and analysed by CyTOF (Figure 1B, Supplementary Table 1). Viable immune cells were 106 
manually gated from all acquired events and subsequently clustered by hierarchical-stochastic 107 
neighbour embedding (h-sne) using Cytosplore software (Figure 1C,2) (35-37). H-sne is a recently 108 
developed method in which t-distributed stochastic neighbor embedding (t-sne) is performed 109 
sequentially to cluster first global cell populations, each of which is then in turn clustered into 110 
subpopulations.   111 
Based on the expression of 37 markers, a total of 199,426 immune cells from all subjects were 112 
divided into nine lineages (CD8+ T cells, CD4+ T cells, myeloid cells, innate lymphoid cells, B cells, 113 
double-negative T cells, granulocytes, CD117+ cells and plasma cells, in order of decreasing 114 
abundance). These cell lineages were further divided into twenty-two subpopulations and 293 115 
clusters (Figure 1C and Table 2). Cell numbers were normalized to the number of stromal cells for 116 
each subject to correct for varying biopsy yields. Normalized abundancies were then compared 117 
between carriage– and carriage+ subjects for each of the lineages, subpopulations and clusters. 118 
There were no significant differences in frequencies between total lineages or subpopulations 119 
between carriage– and carriage+ subjects. However, at a finer level seven clusters were significantly 120 
higher in carriage– than in carriage+ subjects (Figure 1C, blue bars). Of note, three B cell clusters 121 
were higher in carriage– subjects (Figure 1C). Moreover, three CD8+ T cell clusters, all expressing 122 
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CD161, and one CD8dim T cell cluster were higher in carriage– subjects than in carriage+ subjects 123 
(Figure 1C). The seven significant clusters strongly correlated (r>0.70) with eighty-eight clusters in 124 
other lineages/subpopulations, sixty-eight of which were in B or T cell lineages, highlighting an 125 
interconnectivity between B and T cell subpopulations in the human nasopharynx (Figure 1C). We 126 
also investigated whether Spn load was associated with cluster abundance to determine the effect 127 
of cell clusters on the control of bacterial load. At day 2, four clusters were significantly negatively 128 
correlated with Spn density, including the CD8dim T cell cluster (r=-0.51, p=0.023) and one of the 129 
CD161+ CD8+ T cell clusters (r=-0.51, p=0.021) that was increased in carriage– subjects over 130 
carriage+ subjects. The other two clusters that negatively associated with density were also were 131 
CD8+ T cell clusters, with one expressing CD161. At day 7, only two clusters were significantly 132 
associated with Spn density: the CD8dim T cell cluster (r=-0.55, p=0.011) and one B cell cluster (r=-133 
0.45, p=0.049).   134 
Nasal B cells are depleted during pneumococcal carriage 135 
We then further investigated the three B cell clusters that were higher in carriage– subjects (Figure 136 
3A,B). All three significantly higher clusters (cluster 4, 9 and 17) expressed CD45RA, HLA-DR, 137 
CD19, CCR6 and CCR7 to varying degrees. None of these clusters expressed CD38, a marker for 138 
plasmablasts, or CD5, a marker for innate B cells (38, 39). Cluster 9 was 2.9-fold higher in carriage– 139 
subjects (p = 0.047) and cells in this cluster expressed also low levels of CXCR5 and CD27. Cluster 140 
17 (2.0-fold higher, p = 0.049) additionally expressed the B cell activation marker CD69. To assess 141 
whether the higher frequency in carriage– subjects was related to increased B cells in carriage– 142 
subjects or decreased B cells in carriage+ subjects, we longitudinally measured CD19+ B cell 143 
frequencies in nasal microsamples collected from an independent cohort (Figure 3C and 144 
Supplementary Figure 1A). Compared to baseline, B cell levels decreased following pneumococcal 145 
carriage at days 2 (2.1-fold, p = 0.048), 6 (2.8-fold), 9 (2.0-fold) and 27 (3.1-fold, p = 0.028) post-146 
inoculation. In the carriage– group, B cell levels decreased 1.1-fold at days 2 and 6, increased 1.2-147 
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fold at day 9 and decreased 1.2-fold at day 27, respectively and were thus relatively stable. The fold-148 
change decrease in nasal B cell levels did not associate with Spn density at any timepoint.  149 
Pneumococcal carriage increases circulating plasmablasts 150 
We hypothesized that the depletion of B cells from the nasal mucosa following carriage 151 
establishment was due to a re-circulation of activated B cells. Although, none of the B cell clusters 152 
that were lower in the carriage+ group expressed the plasmablast marker CD38, it has been 153 
demonstrated previously that memory B cells differentiate rapidly intro plasmablasts upon activation 154 
(40). Therefore, we measured numbers of Spn-specific and total plasmablasts in peripheral blood 155 
mononuclear cells (PBMC) collected before and after carriage establishment using a flow cytometry-156 
based assay (Supplementary Figure 1B). During carriage, the frequency of 6B polysaccharide-157 
specific plasmablasts among total B cells increased while the frequency of plasmablasts specific to 158 
the pneumococcal protein pneumolysin remained unaltered (Figure 4A). As a negative control we 159 
measured levels of plasmablasts specific for an unrelated Spn capsular type (15B), which were not 160 
affected as expected. However, the frequency of total circulating plasmablasts among all B cells 161 
increased (median 1.5x, IQR: 1.2-2.8x; p = 0.008) suggesting that nasal B cells became non-162 
specifically activated during carriage. Similar results were obtained when normalizing to the total 163 
number of lymphocytes, demonstrating this was not due to other shifting B cell populations 164 
(Supplementary Figure 2A). We then investigated CCR10 expression on these plasmablasts, which 165 
has been reported to mark IgA secreting cells (41) and is potentially important for homing of B cells 166 
to mucosal tissues including the airways (42, 43). The total population of plasmablasts post carriage 167 
displayed reduced numbers of CCR10+ cells, in contrast to 6B-specific plasmablasts, indicating 168 
differential expansion between specific and non-specific B cell populations (Figure 4B). This is 169 
supported by the observation that increased circulating levels of 6B polysaccharide-specific 170 
plasmablasts inversely correlated with the nasal B cell CyTOF clusters 9 and 20, while total 171 
plasmablast increases inversely correlated with the CyTOF B cell clusters 21 (Figure 4C). Clusters 172 
9 and 21 still negatively correlated with levels of circulating 6B-specific and total plasmablasts, 173 
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respectively, after normalization to total lymphocyte numbers (Supplementary Figure 2B). Thus, we 174 
wanted to assess whether both Spn-specific as well as unrelated B cells became activated following 175 
carriage, leading to recirculation. We therefore measured antibody levels in serum against not only 176 
Spn but also Streptococcus pyogenes, Staphylococcus aureus and Haemophilus influenzae as 177 
these are common colonizers of the human nasopharynx and thus nasal B cells against these 178 
bacterial species are likely present in the nose of most individuals. Following Spn colonization, IgG 179 
levels specific for Spn (median 1.4x, IQR: 1.1-2.4) and Haemophilus influenzae (median 1.2x, IQR: 180 
1.1-1.5) significantly increased, while IgG levels specific for Streptococcus pyogenes and 181 
Staphylococcus aureus were not significantly altered (Supplementary Figure 3A). Serum IgA 182 
concentration only increased for Spn and not for Haemophilus influenzae (Hi) or any of the other 183 
bacterial species (Supplementary Figure 3B). To investigate whether this observed increase in 184 
Haemophilus-specific IgG was due to an increase in cross-reactive antibodies, directed against for 185 
example the surface antigen choline phosphate (ChoP) or the capsular polysaccharide (44, 45), we 186 
also measured Haemophilus-specific IgG titers following absorption with whole cell pneumococcus 187 
(Supplementary Figure 3C). This abrogated the increased titers against Hi post carriage, indicating 188 
this was likely due to cross-reactivity. Similarly, in nasal wash, levels of IgA against Spn and Hi were 189 
increased, whereby the latter also was prevented by pre-absorption of nasal wash with Spn 190 
(Supplementary Figure 3D,E). 191 
Nasal CD8 Tissue-resident memory T cells are higher in carriage– subjects 192 
The three clusters of CD8+ T cells and the cluster of CD8dim T cells that were higher in carriage– 193 
subjects all expressed CD69, a marker of tissue-resident memory (Trm) cells (Figure 5A). To verify 194 
that these CD69+ CD8+ T cells represented Trm cells, we measured the expression of CD103 and 195 
CD49a on CD69+ and CD69- cells by flow cytometry from a representative biopsy (Supplementary 196 
Figure 4A). Indeed, 89.1% of nasal CD69+ CD8+ T cells expressed CD103 and CD49a, confirming 197 
that these were Trm cells (Figure 5B) (46). The markers CD5, CD38, HLA-DR, CCR6, CD127, CCR7 198 
and CD11c were expressed in cluster-specific patterns and at varying intensities among the 199 
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significant clusters. This suggests that clusters of cells with varying degrees of activation and 200 
memory types were enriched in carriage– subjects. One cluster expressed only low levels of CD8 201 
(cluster 10 of CD8dim T cells, 2.0-fold higher, p = 0.016), which could reflect cytotoxic effector memory 202 
cells (47). We then stimulated nasal biopsy cells and PBMC overnight with PMA and ionomycin to 203 
assess the functional capacity of nasal CD8+ T cells (Figure 5C). Among nasal CD8+ T cells, 94.8% 204 
produced tumor necrosis factor alpha (TNF) and/or interferon gamma (IFN-ɣ) following stimulation, 205 
compared to 36% of blood CD8+ T cells, demonstrating that nasal CD8+ T cells are highly functional.  206 
Baseline circulating MAIT functionality associates with resistance to pneumococcal carriage 207 
Three of the four significant clusters expressed CD161, a marker for mucosal associated invariant T 208 
(MAIT) cells, and we therefore tested the hypothesis that MAIT cell responses against Spn were 209 
associated with protection against carriage. PBMC collected prior to pneumococcal challenge were 210 
stimulated in vitro with heat-inactivated Spn and activation (CD69) and cytokine production (TNF, 211 
IFN-ɣ and IL-17A) were assessed (Supplementary Figure 4B). MAIT cells of both carriage– and 212 
carriage+ groups upregulated CD69 after a 3-day culture with heat-inactivated Spn (Supplementary 213 
Figure 4C). However, only MAIT cells from carriage– subjects produced increased levels of TNF and 214 
IFN-ɣ, but not IL-17A, upon restimulation in vitro with heat-inactivated Spn (Figure 5D). Conversely, 215 
MAIT cells from carriage+ subjects did not produce increased levels of any cytokine upon stimulation. 216 
This was specific to MAIT cells as conventional CD8+ T cells responded by producing small amounts 217 
of IFN-ɣ and no TNF (Supplementary Figure 4D). The baseline responses of MAIT cells in blood 218 
upon restimulation showed a positive correlation with numbers of nasal cells at ten days post 219 
pneumococcal challenge in CyTOF CD161+ CD8+ T cell cluster 9, which was significantly higher in 220 
the carriage– group (r = 0.54, p = 0.02, Figure 5E).  221 
To assess the kinetics of nasal MAIT cells, we collected nasal curettes before and at 2 and 6 days 222 
post inoculation in an independent cohort and analysed total MAIT cells by flow cytometry 223 
(Supplementary Figure 5). Total MAIT cell numbers were similar between carriage– and carriage+ 224 
groups at all timepoints, as observed by CyTOF at day 10. Due to the low numbers of cells that can 225 
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be obtained using minimally-invasive curettage, we were not able to longitudinally measure MAIT 226 
cell subsets that were significantly associated with carriage as identified by CyTOF. 227 
Association between baseline IgG and abundance of B and CD8+ T cell clusters 228 
We wanted to further characterize the relationship between abundance of the clusters that were 229 
significantly different between carriage+ and carriage– groups with levels of baseline IgG against Spn 230 
to assess whether recall responses were involved. As previously reported, there was no difference 231 
between carriage+ and carriage– groups in levels of baseline IgG against Spn (Figure 6A) (7, 25, 27). 232 
Of the seven clusters significantly associated with carriage status, one cluster (B cell cluster 9) 233 
showed a positive association between baseline IgG and cluster abundance (Figure 6B). This B cell 234 
cluster also correlated with the increased number of 6B-specific plasmablasts following colonization, 235 
which could suggest that these B cells are linked to production of Spn 6B-specific antibodies.   236 
Nasal monocytes show limited differentiation into macrophages 237 
Monocytes have been previously associated with the clearance of Spn carriage (16, 23), however 238 
these cells have not been previously phenotyped in detail in the human nasopharynx. Of the twenty-239 
five clusters defined in the myeloid lineage, fifteen expressed CD14 (Supplementary Figure 6). Of 240 
these, only two also expressed CD16. Four CD14+ clusters expressed the macrophage markers 241 
CD163 and CD206 and an additional three clusters expressed CD206 but not CD163 (48). However, 242 
alveolar monocytes can express CD206, suggesting this is not a definitive indication of differentiation 243 
(49). The activation markers CD25 and CD86 were present on five monocyte clusters (50). Thus, 244 
monocyte/macrophages in the nose mainly consisted of classical monocytes with limited 245 
differentiation into macrophages.  246 
Characterization of nasal CD4+ memory T cells 247 
CD4+ T memory cells, in particular Th17 cells, were previously found to be critical for Spn immunity 248 
in mice models of nasal colonization (15, 16). Of all cells in the CD4+ T cell lineage, 89.6% expressed 249 
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the memory marker CD45RO. Of these, 60.3% expressed CD161, a marker that has been proposed 250 
to identify Th17 cells (51, 52). Another 4.6% of memory cells was defined by expression of high 251 
levels of CD25, a marker for regulatory T cells. We defined twenty-three clusters of CD161– CD4+ T 252 
memory cells, twenty-one clusters of CD161+ CD4+ T memory cells and nine clusters of CD25hi CD4+ 253 
T memory cells (Supplementary Figure 7). All CD4+ T memory cell clusters expressed a combination 254 
of the markers CD7, CD127, HLA-DR, CD38 and CD69 demonstrating a wide range in activation 255 
and differentiation status (46). The CD25hi CD4+ T memory cells likely were regulatory T cells as 256 
they were predominantly negative for CD127 and two of these clusters expressed cytotoxic T-257 
lymphocyte-associated protein 4 (CTLA-4) and CD27 (53). CD161 was not restricted to Th17 cells 258 
as among CD161+ CD4+ T memory cells, two clusters expressed also CD8 and were thus double-259 
positive T cells (54). In addition, two clusters expressed CD25 without CD127 expression indicating 260 
regulatory T cells, and one cluster expressed chemoattractant receptor-homologous molecule 261 
expressed on Th2 cells (CRTH2), a marker of Th2 cells (55).  262 
Cellular distribution through the nasal mucosa 263 
We then performed immunohistochemistry on a biopsy from a challenged but carriage– subject to 264 
further understand the distribution of these cells through the mucosal tissue (Figure 7). CD4+ T cells 265 
were found predominantly in the subepithelial layer (Figure 7C,D), while CD8 and CD161 were also 266 
found at the epithelial layer (Figure 7E,F). Similar to CD4+ T cells, B cells (defined by CD20) were 267 
mostly observed in the sub-epithelium, while myeloid cells (CD68) could be seen at both the 268 
epithelial and sub-epithelial layer (Figure 7G,H). Neutrophils were found abundantly at the epithelial 269 
surface but also in the sub-epithelium (Figure 7I,J).   270 
Discussion 271 
This study comprehensively characterised immune cells in biopsies collected from the human nasal 272 
mucosa. As nasal samples were collected ten days following experimental human pneumococcal 273 
challenge, we were able to associate the frequency of specific immune populations with Spn 274 
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carriage. Given the difficulty in access to such tissue samples, especially in a setting where the onset 275 
of infection is known, this provided a unique opportunity to investigate mucosal immune responses 276 
not undertaken previously. The application of CyTOF led to a broad and comprehensive study of 277 
cellular subsets involved in immunity against Spn carriage, deriving 293 immune clusters belonging 278 
to nine cellular lineages. Clusters belonging to B cells and CD8+ CD161+ T cells were higher in 279 
carriage– subjects. In addition to carriage status, we also associated Spn density with cluster 280 
abundance. Several CD8+ T cell clusters negatively correlated with Spn load, further supporting a 281 
protective function for these cells.  282 
B cells were depleted from the nasal mucosa following the establishment of Spn carriage. This 283 
depletion correlated on an individual level with increased numbers of circulating 6B polysaccharide 284 
specific and total plasmablasts. Thus, this depletion likely was due to recirculation of activated B 285 
cells rather than due to apoptosis of nasal B cell upon Spn polysaccharide capsule encounter as has 286 
also been described (56). The total plasmablast expansion, but not 6B plasmablast expansion, was 287 
characterized by a decreased proportion of CCR10+ cells, suggesting a preferential expansion of 288 
CCR10– cells or a downregulation of this marker. The correlation between low numbers of cells in 289 
specific nasal B cell clusters with increased levels of circulating plasmablasts indicates that activation 290 
of nasal B cells during carriage led to B cell re-circulation. In particular numbers of B cell cluster 9, 291 
which was lower in carriage+ subjects, associated with 6B PS-specific plasmablasts, as well as with 292 
levels of pneumococcus-specific antibodies in serum. Indeed, trafficking of memory B cells between 293 
airways and blood has been reported (57).  294 
Levels of serum IgG against Hi increased following colonization with Spn, due to an induction of 295 
cross-reactive antibodies, as pre-absorption with Spn abrogated this increase. Thus, pneumococcal 296 
colonization has an effect on mucosal and systemic B cell populations and antibodies that bind both 297 
pneumococcus and Hi. The negative association between Spn and Hi in the human nasopharynx is 298 
well described and this observation could be added to the potential mechanisms that underlie this 299 
interaction, such as Hi-mediated recruitment of neutrophils and clearance of pneumococcus (58). B 300 
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cells express the innate receptors TLR2 and TLR4 (59), which can be activated by pneumococcus, 301 
and we thus hypothesized that pneumococcal carriage leads to non-specific activation of B cells. 302 
Neisseria lactamica has been previously demonstrated to be able to aspecifically activate innate B 303 
cells (60, 61). However, the increased antibody responses against Hi were likely due to induction of 304 
cross-reactive antibodies and we observed no increase in serum IgG levels against Streptococcus 305 
pyogenes or Staphylococcus aureus, two other common nasal colonizers. 306 
Several nasal CD8+ Trm cell clusters were higher in subjects protected from Spn carriage. These 307 
cells were previously found to be protective against influenza infection in murine models (62). Spn 308 
is classically thought of as an extracellular bacterium and therefore the role of CD8+ T cells in 309 
controlling Spn has not been extensively studied in humans. However, it was recently shown that 310 
Spn can replicate within splenic macrophages and can reside within epithelial cells, suggesting that 311 
CD8+ T cell immunity could be elicited by Spn and play a role in protection against Spn carriage or 312 
disease (63, 64). Indeed, Spn protein specific CD8+ T cells could be readily detected in blood of 313 
Gambian adults (65). In murine models, CD8+ T cells were found to be protective against Spn lung 314 
infection but did not have an effect on nasopharyngeal carriage (19, 66). 315 
We found here that CD8+ MAIT cell functionality before pneumococcal challenge associated with a 316 
resistance to carriage acquisition. MAIT cells were recently reported to be able to recognize Spn 317 
through MHC class I-related protein 1 (MR-1) dependent and independent pathways (67). MAIT cells 318 
were previously found to be important in the protection against lung bacterial and viral infections via 319 
direct and indirect responses (68). Our findings now suggest these cells could also protect against 320 
nasopharyngeal Spn colonization. Given the abundance of MAIT cells at the nasal mucosa and their 321 
specificity for precursors from the riboflavin synthesis pathway, which is highly conserved in the Spn 322 
genome (67), these cells are excellently placed to initiate an immune response upon exposure to 323 
Spn. The rapid production of cytokines as TNF and IFN-γ by these cells upon Spn encounter could 324 
lead to the recruitment or activation of neutrophils and monocytes, which in turn could phagocytose 325 
Spn and protect against carriage acquisition (69). Baseline MAIT functionality in blood positively 326 
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correlated with cell numbers within one of the nasal CD8+ CD161+ cell clusters, suggesting trafficking 327 
of MAIT cells from the blood to the nose upon pneumococcal encounter. Indeed, MAIT cells have 328 
been shown to be depleted from the circulation and accumulate in tissues upon infection (70, 71).   329 
One limitation of this study is that the number of granulocytes measured was very low due to the 330 
overnight resting step following enzymatic digestion. While this resting step allowed for the return of 331 
markers that were cleaved by the enzymatic digestion, neutrophils quickly become apoptotic after 332 
being removed from the body (72-74). Consequently, the characterization of granulocytes reported 333 
here is incomplete and we were not able to assess whether specific neutrophil subsets are 334 
associated with protection against pneumococcal colonization.  335 
In addition, due to the invasiveness of sample acquisition, sample size was limited and we were not 336 
able to characterize nasal biopsies at various time points. Thus, no baseline was available making 337 
it impossible to conclude whether differences between carriage– and carriage+ groups were present 338 
at baseline or occurred in the ten days following inoculation. In addition, we were not able to assess 339 
transient responses early after bacterial inoculation. To address this caveat, we longitudinally 340 
measured levels of nasal B cells and MAIT cells collected by nasal curettes in independent cohorts. 341 
This analysis demonstrated that B cells were depleted from the nose upon colonization. In contrast, 342 
we did not observe any changes in total numbers of MAIT cells. Using CyTOF we observed that 343 
MAIT cell clusters expressing the markers CD7, CD69, CD5 and CCR6 or CD38, but not total 344 
number of MAIT cells, were higher in the carriage– group. Thus the larger amount of cells obtained 345 
from nasal biopsies combined with the broad analysis by CyTOF allowed us to identify sub-346 
populations of MAIT cells associated with protection against colonization. 347 
This study revealed some notable differences from previously conducted experiments with murine 348 
models. In particular, we did not see any association between Th17 cells, or any CD4+ T memory 349 
cells, and control of colonization as previously reported (15, 16). This agrees with previous 350 
observations from experimentally colonized adults that nasal IL-17A levels are not increased (24). 351 
Moreover, there was no association between monocytes and Spn colonization status or density, 352 
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unlike what was previously reported in murine models or humans followed up longitudinally following 353 
experimental colonization (16, 20, 24). This is possibly because we terminated carriage after day 354 
seven for safety reasons prior to collecting biopsies, making it impossible to associate immune cell 355 
clusters, such as monocytes, with Spn clearance which typically occurs after day 10. Moreover due 356 
to relatively small numbers of individuals in this controlled human infection study, it is possible that 357 
subtle associations between cell populations and bacterial load were missed. This study however 358 
does provide a unique characterization of monocytes/macrophages phenotype in the human nose, 359 
which show remarkably little differentiation into macrophages. Another remarkable difference 360 
between this study and findings from murine models is that we observed a protective effect of MAIT 361 
cells against colonization, while depletion of CD8+ T did not affect immunological Spn control in 362 
mouse models (19). MAIT cells are a recently identified T cell subset that is common in humans, 363 
consisting of up to 10% of all T cells in the circulation, but that is very rare in mice (68). It is possible 364 
that this difference has led to an underappreciation of the CD8+ T cell’s role in protection against 365 
pneumococcal carriage in humans. Finally, our finding of an activation and exodus of B cells from 366 
the nose merits further attention and validation using tractable mouse models to understand its role 367 
in the generation of humoral immunity against Spn and cross-reactive protection against 368 
Haemophilus influenzae. 369 
In conclusion, this study provides both a broad and an in-depth view of the adult human nasal 370 
immune system in the setting of experimental human pneumococcal challenge. Nasal B cells were 371 
depleted following carriage establishment, likely due to differentiation to plasmablasts and 372 
recirculation. In addition, CD8+ MAIT cell responses were associated with protection from Spn 373 
carriage.  374 
Methods 375 
Study design and sample collection 376 
Healthy adult subjects were screened for the presence of natural pneumococcal carriage in nasal 377 
wash samples (NW) using classical microbiology (7, 34, 75). Subjects not naturally carrying 378 
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pneumococcus were then inoculated with 80,000 CFU per nostril of 6B type Spn as described (7, 379 
75). Development of nasal carriage was monitored using NW samples collected at days 2 and 7 post 380 
inoculation. Growth of pneumococcus from NW samples at any time-point defined carriage positive 381 
volunteers. All subjects then received a three-day course of amoxicillin and underwent a 4mm nasal 382 
biopsy at day 10 post inoculation. The nasal cavity was first sprayed up to six times with lidocaine 383 
hydrochloride 5% with phenylephrine hydrochloride 0.5%.  Five to ten minutes later the infero-medial 384 
part of the inferior turbinate, i.e. the point of incision, was injected with up to 1 mL of lidocaine 385 
hydrochloride 2% with adrenaline 1:80 000. An incision of approximately 5 mm with No.15 blade was 386 
then made and 2-4 mm of mucosal tissue was removed with Tillies Henckle’s surgical forceps. This 387 
study was registered under ISRCTN85509051. Nasal curettes (ASL Rhino-Pro©, Arlington 388 
Scientific) were collected from an additional cohort (ISRCTN16993271) of subjects inoculated with 389 
the same 6B strain. The outcomes reported in this manuscript were a priori included in the study 390 
protocols. 391 
Nasal biopsy digestion 392 
Nasal biopsies were finely cut using a sterile scalpel size 11 (Fisher Scientific). Pieces were then 393 
incubated in 20mL pre-warmed RPMI 1640 (Fisher Scientific) with Liberase TL (250μg/mL, Sigma) 394 
and DNAse I (50μg/mL, Sigma). Fragments were incubated for 45 minutes at 37°C, while shaking 395 
at 250rpm at a 10° angle. At the end of the digestion, biopsies were passed five times through a 16-396 
gauge blunt-ended needle (Fisher Scientific) and the digested sample was filtered over a 70um filter 397 
(Fisher Scientific). This process was repeated for any remaining fragments. Cell were spun down for 398 
10 minutes at 400xg and then red blood cells were lysed using an osmotic lysis buffer. Cells were 399 
washed with RPMI with 20% heat-inactivated fetal bovine serum (FBS, Fisher Scientific), 400 
resuspended at 106 cells/mL in RPMI with 20% FBS and rested overnight. The next day, cells were 401 
counted and washed with RPMI + 10% FBS. Cells were stained as a viability marker using 1µM 402 
intercalator Rh-103 (Fluidigm) for 15 minutes, washed and fixed with 1.8% paraformaldehyde 403 
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(Sigma) for 15 minutes. Cells were washed and stored in liquid nitrogen in CTL-CryoTM ABC media 404 
(Cellular Technology Limited) until CyTOF barcoding and staining.  405 
Mass cytometry staining and analysis 406 
Nasal biopsy cells were thawed on ice and barcoded using the Cell-ID 20-plex Pd Barcoding Kit as 407 
per manufacturer’s instructions (Fluidigm). The effect of fixation on epitopes detected by the included 408 
antibody clones was tested using PBMCs and monocyte-derived dendritic cells. Following three 409 
washes with staining buffer (Fluidigm) and 10 minutes of FcR blocking (Biolegend) pooled cells were 410 
stained for 45 minutes at room temperature with the antibody cocktail (Supplementary Table 1). All 411 
Fluidigm antibodies were pre-conjugated to metals while all other antibodies were conjugated using 412 
a total of 100 μg of purified antibody combined with the MaxPar X8 Antibody Labelling Kit (Fluidigm) 413 
according to manufacturer’s protocol V7 and stored in 200 µL Antibody Stabilizer PBS (Candor 414 
Bioscience) at 4°C. Cells were washed twice with staining buffer and incubated for 1 hour with 1000x 415 
diluted 125 μM Cell-ID intercalator-Ir (Fluidigm) to stain DNA. Cells were washed 3 times with 416 
staining buffer and 2 times with de-ionized H2O prior to addition of normalization beads (Fluidigm) 417 
and acquisition on a Helios 2 mass cytometer (DVS Sciences). CyTOF Fcs files were normalized 418 
using the included beads, concatenated and debarcoded as per manufacturer’s instructions. The 419 
debarcoding step leads to a removal of doublets (76). Then, viable immune cells were pre-grated 420 
(Figure 2) and exported as .fcs files using Flowjo X (Treestar). These were further analysed using 421 
Cytosplore (https://www.cytosplore.org/). 422 
Nasal B and MAIT cell phenotyping 423 
Immunophenotyping of nasal B and MAIT cells obtained by curettes was performed as described 424 
(29). In brief, cells were dislodged from curettes and stained with LIVE/DEAD® Fixable Aqua Dead 425 
Cell Stain (ThermoFisher) and an antibody cocktail containing among others Epcam-PE, HLADR-426 
PECy7, CD66b-FITC, CD19-BV650 (all Biolegend), CD3-APCCy7, CD14-PercpCy5.5 (BD 427 
Biosciences) and CD45-PACOrange (ThermoFisher) for B cells, while the cocktail for MAIT cells 428 
included also CD8–BV785 and TCRva7.2-BV711 or TCRva7.2-PE-TxsRed and CD45-BV510 429 
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(Biolegend). Samples were acquired on a LSRII flow cytometer and analysed using Flowjo X 430 
(Treestar). Fluorescent minus one controls for each of the included antibodies were used to validate 431 
results during set-up of all of the panels used. Samples with less than 500 immune cells or 250 432 
epithelial cells (11.9% of all nasal samples) were excluded from further analysis. A full list of all 433 
antibodies used for flow cytometry is provided in Supplementary Table 2). 434 
Intracellular cytokine staining following PMA/Ionomycin or pneumococcus stimulation 435 
For intracellular cytokine staining after PMA and Ionomycin stimulation, fresh nasal biopsy cells or 436 
PBMC were stimulated with 100 and 500 ng/mL of these, respectively. After 2 hours, Golgiplug™ 437 
(BD Biosciences) was added and cells were incubated for another 16 hours. Cells were washed and 438 
stained extracellularly with LIVE/DEAD® Fixable Violet Dead Cell Stain (ThermoFisher) for 15 439 
minutes and then for another 15 minutes with CD161-APC, CD69-BV650, CD25-PEDazzle594, 440 
CD103-BV605, CD4-PercpCy5.5, CD8-AF700, TCRvα7.2-BV785 (all Biolegend) and CD3-APH7 441 
and TCRgd-PECy7 (BD Biosciences). Cells were then permeabilized using the eBioscience™ Foxp3 442 
Transcription Factor Staining Buffer Set (Fisher Scienctific) following the manufacturer’s protocol. 443 
Intracellular staining was done for 30 minutes with FOXP3-AF488, IFNg-PE, TNFa-BV711 444 
(Biolegend) and IL17A-BV510 (BD Biosciences). Finally, cells were washed, resuspended in 200µL 445 
PBS and acquired on a LSR2. 446 
For staining with pneumococcus, PBMC were thawed with 50μg/mL DNAse I (Sigma) in pre-warmed 447 
RPMI + 10% FBS and washed twice, once in media including DNAse I and once in media without 448 
DNAse I. Cells were rested overnight and then cultured at 5x105 cells in 500uL media with 5ug/mL 449 
(corresponding to 4.3x10^7 CFU/mL) heat-inactivated type 6B Streptococcus pneumoniae or left 450 
unstimulated as a control. After 48 hours, fresh antigen was added to the cells and 2 hours later 451 
Golgiplug was added and cells were treated as above. 452 
Pneumococcal-specific B cell detection 453 
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Purified pneumococcal polysaccharides 6B and 15B (Oxford Biosystems) and Pdb were diluted to 454 
100µg/mL in purified H2O and biotinylated using the One-Step Antibody Biotinylation Kit (Miltenyi) 455 
as per manufacturer’s instructions. Biotinylated proteins were then 2x dialysed for 45 minutes against 456 
1L PBS using Slide-A-Lyzer™ MINI Dialysis Device, 3500 molecular weight cut off (ThermoFisher) 457 
and stored at 4ºC until labelling. Biotinylated 15B, 6B and Pdb were then mixed in a 4:1 molecular 458 
ratio (Pdb), or a 1:1 molecular ratio (polysaccharides), with PE-streptavidin, BV785-streptavidin or 459 
FITC-streptavidin (Biolegend), respectively. Incubation was performed on ice in a stepwise approach 460 
where 1/10 fraction of streptavidin conjugate was added to the antigen followed by a ten-minute 461 
incubation. After the final incubation, 1 pmol free biotin was added and the mixture was incubated 462 
for 30 minutes on ice. Labelled antigens were stored at 4ºC and used within two weeks.   463 
To stain cells, PBMC were thawed with 50μg/mL DNAse I (Sigma) in pre-warmed RPMI + 10% FBS 464 
and washed once in media including DNAse I. Cells were then resuspended in PBS containing 465 
LIVE/DEAD® Fixable Violet Dead Cell Stain (ThermoFisher) with 10µg/mL purified streptavidin (to 466 
block aspecific binding, Biolegend) for 15 minutes. Then labelled antigens and an antibody cocktail 467 
containing CD71-AF700 (BD Biosciences), CD19-BV605, CD27-PE/Cy7, CD38-APC/Cy7, CD69-468 
BV510 and CCR10-APC (all Biolegend) was added and cells were incubated for another 15 minutes. 469 
Finally, cells were washed, resuspended in 200µL PBS and acquired on a LSR2. 470 
Immunohistochemistry 471 
A nasal biopsy was fixed in 4% PFA for 16-24 hours before rinsing in 50% and 70% ethanol. This 472 
was embedded in Paraffin, cut into 4µm sections, dewaxed, subjected to antigen retrieval (95ºC for 473 
15 minutes in Sodium Citrate Buffer (pH 6) and processed for immunohistochemistry as published 474 
(77). In short, sections were permeabilised in methanol for 15 minutes with 1% hydrogen peroxide. 475 
After rinsing in PBS, primary antibodies were diluted in goat (or horse) serum buffer (1% BSA, 4% 476 
goat (or horse) serum, 0.01% sodium azide in PBS). Primary antibodies used were: CD3 (Dako), 477 
CD4, CD20, CD66b, CD68, CD11b (Abcam), CD8 (Epitomics) and CD161 (Atlas antibodies), which 478 
were applied over night at 4ºC (Supplementary table 3). Sections were rinsed in PBS and secondary 479 
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biotinylated antibodies (Vector lab) were applied for 45 mins at RT. Slides were rinsed and a complex 480 
of avidin and biotin (ABC) solution was added to sections for 60 minutes which was prepared 30 481 
minutes prior incubation After rinsing, NovaRed™ (Vector®, Burlingame, CA, U.S.A) chromogen 482 
was prepared to manufacturer's instructions. Sections were counterstained, dehydrated, placed in 483 
xylene and mounted for microscopy and scanned using the nanozoomer digital pathology (NDP, 484 
Hamamatsu, Photonics KK). Pictures were processed using the NDPview 2 software (version 2.6.13; 485 
Hamamatsu Photonics KK). 486 
ELISA  487 
Serum IgG and IgA titres against Streptococcus pneumoniae, Streptococcus pyogenes, 488 
Staphylococcus aureus and Haemophilus influenzae were quantified in serum samples, whereas 489 
nasal mucosa IgG and IgA titres against Streptococcus pneumoniae and Haemophilus influenzae 490 
were measured in nasal wash samples using whole cell ELISA. The ELISA was performed on 491 
MaxiSorp™ 96 well plates (Nunc). Per pathogen, 100μL of 108 CFU/mL was prepared in carbonate 492 
buffer pH 8, added to the plates and allowed to adhere to the wells for 16 hours at 22°C. Then the 493 
plates were washed three times using phosphate buffered saline (PBS) containing 0.05% Tween 20, 494 
followed by blocking by adding 100 μL of PBS containing 2% Bovine serum albumin. Plates were 495 
incubated at 37°C for 1 hour and were washed before adding serial dilutions of serum samples. For 496 
detection of IgG and IgA, a 1:5000 and 1:4000 dilution of anti-human-IgG (Sigma, A9544, Germany) 497 
and anti-human-IgA (Sigma, A9669, Germany), respectively, was made using 0.1% BSA and 100 498 
µL added to each well after washing and incubated at room temperature for 2 hours. Standard curves 499 
for IgG and IgA were generated based on a standard pool serum (sera of 7 Spn carriers collected at 500 
D23 post challenge). Arbitrary units of IgG and IgA were assigned to the serum standard for each 501 
pathogen. To absorb antibodies cross-reactive against S. pneumoniae, pneumococci were added in 502 
the samples, following 2h incubation at RT and overnight incubation on a rotor at 4o C. The next day 503 
samples were centrifuged at 4,000g for 3min and supernatant was collected and measured as 504 
above. Efficacy of depletion was confirmed by ELISA against Spn post absorption. 505 
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Statistics 506 
Two-tailed, non-parametric statistical tests were used throughout the study. The number of cells in 507 
a cluster for each subject was normalized against the total number of non-immune cells acquired by 508 
CyTOF for that subject to account for number of cells isolated from a given biopsy. This normalization 509 
strategy has the advantage that the normalized frequencies of cells in a cluster is not dependent on 510 
other clusters, which is a major disadvantage of normalizing against total immune cells. Normalized 511 
cluster abundances were then compared between carriage– and carriage+ subjects for each of the 512 
clusters using the Mann-Whitney test, without correcting for multiple testing. Data was analysed and 513 
graphs were created using ‘pheatmap’ and ‘ggplot2’ packages in R software and circular graph 514 
(Figure 1C) was created using circos software (78). The graphical abstract was created with 515 
BioRender 516 
Data availability 517 
Normalized and debarcoded CyTOF fcs files have been deposited in the FlowRepository with 518 
identifier FR-FCM-ZYSE (https://flowrepository.org/).  519 
Study Approval 520 
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Figure and figure legends 
 
Figure 1. Mass cytometry from nasal biopsies following experimental human pneumococcal 
challenge. A) Study design showing pneumococcal inoculation (green bar) and sample collection. 
  29 
Subjects who acquired pneumococcus following challenge are depicted in red (n=8), while those 
protected are depicted in blue (n=12). Antibiotics (abx) were administered in the 3 days leading up 
to biopsy collection (blue area). B) Viable cell yield following enzymatic biopsy digestion for the 
twenty biopsies collected for CyTOF. Individual samples and boxplots, depicting median and 
interquartile ranges, with whiskers extending to 1.5× interquartile range or maximum value, are 
shown. C) Circle diagram showing all 293 defined clusters within 9 lineages and 22 subpopulations. 
From outside in: number of cells in each cluster is depicted by grey bars. Relative expression for 36 
markers is shown with red depicting higher expression (CD45 and Epcam are not depicted). 
Association with carriage state is shown, where blue bars depict the fold-change of the median of 
normalized abundance in carriage– subjects over carriage+ subjects (Mann-Whitney test, p < 0.05 
shown only). Significant correlations between Spn density at either day 2 or day 7 with normalized 
abundance are depicted by circles, with red indicating a negative association. Spearman correlation 
analyses were performed with all subjects where carriage– subjects were included with a density of 
0. Ribbons connect highly correlated (r>0.70) clusters that were associated with Spn carriage status 
not belonging to the same lineage, with colour indicating the lineage of origin. DN_T = double 
negative T cells, Gran = granulocytes, ILC = innate lymphoid cells. 
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Figure 2. CyTOF analysis strategy. A) CyTOF data files were pre-gated using Flowjo to identify cells 
(DNA+ Bead–), followed by selecting viable immune cells (CD45+ Dead–). These cells were exported 
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and loaded in Cytosplore for hierarchical stochastic neighbour embedding (h-sne), in which lineages, 
subpopulations and clusters were sequentially identified in three steps. Gating for naïve CD4+ T cells 
is shown as an example. B) Cells were clustered using all 38 markers minus the epithelial marker 
Epcam and lineages were then defined based on the expression of nine markers. Clustered lineages 
and expression of included markers are shown. Subpopulations for C) CD8+ T cells, D) granulocytes, 
E) CD4+ T cells, F) innate lymphoid cells, G) CD117+ cells and H) double-negative T cells were 
defined based on the expression of the depicted markers. B cells, plasma cells, myeloid cells were 
not further divided into subpopulations due to lack of clear clustering by relevant markers. Cell 
subpopulations were then further divided into clusters using all 38 markers minus the epithelial 
marker Epcam. 
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Figure 3. Nasal B cells are depleted following pneumococcal carriage. A) Heatmap showing the 
expression of thirty-seven markers for all B cell clusters. Clusters were ordered based on similarity 
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and a distance dendrogram is depicted. B) The relative abundance for each of the three significantly 
higher clusters normalized to stromal cells is expressed on a log10 scale for carriage– (Spn–, blue, 
n=12) and carriage+ (Spn+, red, n=8) subjects. Boxplots, depicting median and interquartile ranges, 
with whiskers extending to 1.5× interquartile range or maximum value, and individual subjects are 
shown. C) Levels of CD19+ nasal B cells longitudinally measured by flow cytometry from minimally-
invasive nasal curettes in an independent cohort for carriage– (Spn–, blue, n=52) and carriage+ 
(Spn+, red, n= 42) subjects. Mean and standard error of mean of log2-transformed fold change levels 
to baseline are shown. * p < 0.05 by Wilcoxon test comparing to baseline with Bonferroni correction 
for comparing multiple timepoints. 
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Figure 4. Pneumococcal carriage leads to increased systemic plasmablasts. A) Levels of 6B 
polysaccharide-specific, 15B polysaccharide-specific, Pneumolysin derivative b (Pneumolysin)-
specific or all plasmablast amongst total B cells were measured from PBMC collected at baseline 
(Day -5) and at the time of biopsy (Day 10 post inoculation). Boxplots depicting median and 
interquartile ranges, with whiskers extending to 1.5× interquartile range or maximum value, and 
individual subjects are shown with carriage–  in blue (n=12) and carriage+ in red (n=8). Paired 
samples are connected by dashed lines.  * p < 0.05, ** p < 0.01 by Wilcoxon test comparing a group 
to its baseline. B) Levels of CCR10+ plasmablasts for 6B-specific and total plasmablasts measured 
from PBMC collected at baseline (Day -5) and at the time of biopsy (Day 10 post inoculation). 
Boxplots and individual subjects are depicted with carriage–  in blue and carriage+ in red with paired 
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samples connected by dashed lines.  ** p < 0.01 by Wilcoxon test comparing a group to its baseline. 
C) Correlations between fold-change in levels of 6B PS-specific and total plasmablasts between 
baseline and day 10 against levels of B cell clusters measured by CyTOF. Color and size of symbols 
reflect the Spearman rho value. * p < 0.05 and ** p < 0.01 by Spearman test.  
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Figure 5. Increased MAIT responses associate with protection from carriage. A) Heatmap showing 
the expression of thirty-seven markers for each of the four CD8+ clusters that were significantly 
different between carriers and non-carriers. Non-significant CD8+ T clusters are not shown. Below 
the heatmap, the abundance for each of the significantly higher clusters normalized to stromal cells 
is expressed on a log10 scale for carriage– (blue) and carriage+ (red) subjects. Boxplots depicting 
median and interquartile ranges, with whiskers extending to 1.5× interquartile range or maximum 
value, and individual subjects are depicted. B) Representative flow cytometry contour plot of CD8+ 
CD69+ and CD8+ CD69- T cells, showing CD103 and CD49a tissue resident marker expression on 
nasal biopsy cells (n=4). C) Representative flow cytometry contour plot of unstimulated nasal biopsy 
cells, and nasal biopsy cells and PBMC stimulated overnight with PMA and ionomycin (PI) to assess 
functional capacity (n=4). D) TNF, IFN-ɣ and IL-17A production by CD8+ MAIT cells 
(CD161+TCRvα7.2+) after 3-day in vitro stimulation with heat-inactivated pneumococcus (HI-Spn) or 
left unstimulated for carriage– (blue, n=14) and carriage+ (red, n=8) subjects in PBMC collected at 
baseline. Boxplots and individual subjects, connected by dashed lines, are shown. ** p < 0.01 by 
Wilcoxon test, *** p < 0.001 by Wilcoxon test. E) Correlations between the difference in cytokine 
production (total of TNF and IFN-ɣ) by MAIT cells in vitro stimulated with HI-Spn or left unstimulated 
against CD8+ CD161+ T cell clusters measured by CyTOF (n=20). Colour and size of symbols reflect 
the Spearman rho value. * p < 0.05 by Spearman test. 
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Figure 6. Association between baseline IgG against Spn and cluster abundance. A) Levels of 
baseline IgG levels against whole cell 6B Spn in serum are shown carriage– (blue, n=12) and 
carriage+ (red, n=8) subjects. Boxplots depicting median and interquartile ranges, with whiskers 
extending to 1.5× interquartile range or maximum value, and individual subjects, connected by 
dashed lines, are shown. B) Correlation between abundance of clusters and baseline levels of IgG 
are shown. Individuals subjects and regression lines per group are shown, with 95% confidence 
intervals depicted in grey. *p=0.03 determined by linear model including carriage status and log-
transformed baseline IgG levels.  
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Figure 7. Immunohistochemistry on serial sections of a nasal biopsy. To establish an overall cellular 
distribution in the tissue a 10x magnification is shown for each of the markers. A 40x inset is also 
included to visualize some individual positive cells. A) Haematoxylin and eosin staining showing the 
entire biopsy. Staining of subsequent slices showing the biopsy at the epithelial edge for the markers 
B) negative control, C) CD3, D) CD4, E) CD8, F) CD161, G) CD20, H) CD68, I) CD66b and J) 
CD11b. A scale showing 250µm are added to all panels and a 40x inset is included. Slices were 
counterstained with haematoxylin and eosin. Some background staining of the extracellular matrix 
is present for CD161 (panel F). Biopsy was derived from one challenged, carriage– subject. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  41 
Tables 
Table 1. Volunteer cohort characteristics divided by carriage state. 
 
 
 
Table 2. List of lineages and subpopulations derived from nasal biopsy analysis. For all nine 
lineages and twenty-two subpopulations, the numbers of defined cell clusters are shown. In 
addition, the total numbers of cells within those lineages/subpopulations and the percentage of that 
subpopulation within all cells for carriage– and carriage+ subjects are shown. Memory cells are 
defined as CD45RO+RA– and naïve cells are defined as CD45RO–RA+ 
Lineage Subpopulation Clusters Cells %Carriage– %Carriage+ 
CD8+ T cells CD161+ CD8+ T cells 17 25103 13.0 11.7 
 Naive CD8+ T cells 20 9042 3.8 6.3 
 Memory CD8+ T cells 26 36860 18.1 19.4 
 Total 63 71005 34.9 37.3 
CD4+ T cells CD161+ CD4+ T cells 21 36328 18.7 17.0 
 CD25hi CD4+ T cells 9 2743 1.2 1.9 
 Naïve CD4+ T cells 9 4235 2.2 1.8 
 Memory CD4+ T cells 23 21158 10.5 10.8 
 CD45RO–RA– CD4+ T  6 2743 1.2 1.9 
 Total 68 67207 33.8 33.5 
Myeloid cells - 25 15226 7.4 8.3 
Innate lymphoid 
cells 
CD8–CD16+ ILC 13 3683 2.0 1.5 
 CD8+CD16+ ILC 5 2392 1.1 1.4 
 CD16–CD127+ ILC 4 1550 0.8 0.6 
 CD16–CD127– ILC 9 3417 1.7 1.8 
 Total 31 11042 5.6 5.3 
B cells - 22 10279 5.8 3.7 
CD4–CD8– T cells TCRgd T cells 9 1838 0.8 1.2 
 DN T cells 7 3052 1.6 1.5 
 CD8dim T cells 13 4317 2.2 2.1 
 Total 29 9207 4.6 4.7 
 Carriage–  
(n=12) 
Carriage+  
(n=8) 
Female gender (%) 4 (33.3%) 4 (50%) 
Median age (min-max) 21 (18-44) 23 (20-30) 
Median day 2 Spn density CFU/mL (min-max) - 127.2 (5.8 - 38677.7) 
Median day 7 Spn density CFU/mL (min-max) - 187.5 (0 – 21736.6) 
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Granulocytes CD66b+ Granulocytes 19 5478 2.9 2.4 
 CD66b– Granulocytes 2 662 0.3 0.3 
 Total 21 6140 3.2 2.7 
CD117+ cells CD117+ lymphocytes 8 2566 1.3 1.3 
 CD117+ mast cells 13 2810 1.5 1.2 
 Total 21 5376 8.5 6.2 
Plasma cells - 13 3944 2.0 2.0 
9 22 293 199426 100 100 
 
 
